Editor in chief, Dr Audiey Kao, talks with Dr Matthew Wynia about allocation of critical care resources and clinicians' duty to show up to work during public health emergencies.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Professor john powell joins us for this special edition of Ethics Talk to discuss how a lens of “othering and belonging” can help us navigate our obligations to and relationships with each other, especially during this COVID-19 pandemic.
Gene editing to enhance humans’ adaptability to climate change should consider safety, harm to be averted, succeeding generations, and social consequences.
AMA J Ethics. 2017;19(12):1186-1192. doi:
10.1001/journalofethics.2017.19.12.stas1-1712.
Although effective, opioid agonist therapy is associated with stigma and thus underutilized for treatment of opioid use disorder in incarcerated settings.
AMA J Ethics. 2017;19(9):922-930. doi:
10.1001/journalofethics.2017.19.9.stas1-1709.
Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
“Difficult” patient encounters can be exacerbated by procedural and technological infrastructure that increases access to electronic health records (EHRs).
AMA J Ethics. 2017;19(4):374-380. doi:
10.1001/journalofethics.2017.19.4.stas1-1704.